ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Huntington’s Disease Links Roche And Isis

by Michael McCoy
April 15, 2013 | APPEARED IN VOLUME 91, ISSUE 15

Roche and Isis Pharmaceuticals have formed an alliance to develop treatments for Huntington’s disease based on Isis’ antisense oligonucleotide technology. Roche will pay Isis $30 million up front and could make license and milestone payments of $362 million. The partners will initially focus on an Isis drug candidate that blocks production of all forms of the huntingtin protein, which is responsible for the disease. The candidate was discovered with assistance from CHDI Foundation, a nonprofit devoted to developing Huntington’s therapies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment